HEALTHPOINT Signs International Deal, Expands Reach to Greater China Region via Schmidt Scientific-Taiwan Licensing Agreement Schmidt to Manufacture, Sell Trizenol® Skin Asepsis Technology in Taiwan, Hong Kong, and China
HEALTHPOINT, Ltd., a Texas-based market leader in infection prevention, tissue management, and dermatology products, has announced an international licensing agreement with Taipei-based Schmidt Scientific for Schmidt to manufacture and market HEALTHPOINT’s infection prevention products Triseptin® and Actiprep®. Based on HEALTHPOINT’s patented Trizenol® technology, a fast-acting and persistent topical antiseptic technology, the products are widely used in the U. S. in the fields of surgical scrubbing and patient preoperative prepping.
(PRWEB) March 20, 2002 -
Based market leader in infection prevention, tissue management, and dermatology products, has announced an international licensing agreement with Taipei-based Schmidt Scientific for Schmidt to manufacture and market HEALTHPOINT’s infection prevention products Triseptin® and Actiprep®. Based on HEALTHPOINT’s patented Trizenol® technology, a fast-acting and persistent topical antiseptic technology, the products are widely used in the U. S. in the fields of surgical scrubbing and patient preoperative prepping.
Schmidt, an international organization specializing in the sale and service of products and equipment for healthcare, science and industry, will manufacture and market Triseptin, a brush-free surgical scrub, and Actiprep, a patient preoperative skin preparation, to medical institutions in the Greater China region. Additionally, Triseptin will be marketed to consumers as an antibacterial hand and body wash under Schmidt Group Practice Company, an affiliate of Schmidt Scientific Taiwan.
The combined market for the products in Taiwan, Hong Kong, and PeopleÂ’s Republic of China is an estimated 1.23 billion people and nearly 70,000 hospitals.
“Triseptin and Actiprep raise the standard of care for surgical scrubbing and preoperative skin preparation,” said H. Paul Dorman, HEALTHPOINT Chairman and CEO. “We are delighted to have Schmidt as our partner to take the technologies into this extensive market.”
“This agreement forms a firm foundation for HEALTHPOINT to extend its innovative skin asepsis technology and products as well as to provide a platform for future growth in the Asia Pacific region,” said Jay Nisbet, Director of International Business Development for HEALTHPOINT.
“Schmidt Scientific Taiwan Ltd. is very pleased to be HEALTHPOINT’s partner in Greater China,” said Henry H. Lee, Chairman and CEO, Schmidt Scientific Taiwan. “We believe there is significant market potential for innovative skin asepsis products.”
Triseptin and Actiprep represent the latest technology introduced in the field of surgical skin asepsis since the introduction of chlorhexidine gluconate (CHG) in the 1970s. (CHG was heretofore recognized as a leading active for surgical scrubs and patient preparation for surgery.) Triseptin and Actiprep are composed of three key elements: a fast-acting, broad-spectrum antimicrobial active ingredient — ethyl alcohol; emollients with surfactants to condition the skin and remove dirt and organic debris; and a preservative system to help prolong the antimicrobial action of alcohol.
Triseptin is the only brush-free surgical scrub with a water-aided formula; water helps removes dirt and organic debris between operative procedures. Other traditional preoperative asepsis products require scrubbing, often with a surgical scrub brush, for five or ten minutes, but Triseptin requires only two 90-second applications and no brush due to its unique surfactants and long-lasting persistence — differences important to a surgical staff that traditionally scrubs multiple times daily.
Actiprep, heralded as a “quick and easy” patient preoperative skin preparation, conserves valuable time in the operating room. Its three main ingredients — like Triseptin’s — provide 24-hour efficacy. According to HEALTHPOINT, doctors, nurses, and other operating room personnel formerly were limited to a “scrub and paint” product that required three or four minutes to apply and three times that long to dry. Actiprep, via a single application, takes under a minute to apply and about a minute to dry — a total prep time of less than two minutes.
Both Triseptin and Actiprep are effective against multi-resistant microorganisms as well as viruses and gram negative and gram positive bacteria. The products have demonstrated superior efficacy and persistence in thorough in vivo studies in accordance with the U. S. Food and Drug AdministrationÂ’s Tentative Final Monograph for Healthcare Antiseptic Drug Products for surgical scrubbing.
Since its inception in 1992, HEALTHPOINT has established a strong domestic U. S. presence in the research, development, and marketing of branded pharmaceuticals, over the counter drugs, and medical devices for infection prevention, tissue management, and dermatology. The companyÂ’s aggressive research and development efforts have taken unique technologies to the market, setting the pace for a highly trained field sales organization that is expanding across North America and beyond.
“We’re an energetic, dynamic organization,” said Mr. Dorman, “and we look forward to taking our products and services to new markets around the world.”
HEALTHPOINT, a DFB Pharmaceuticals, Inc. affiliate company, is based in Fort Worth, Texas.
DFB, through its affiliate companies, contract partners, and branded marketing organizations, provides technology-driven products, outsourcing services and licensing opportunities for the healthcare industry worldwide.
DPT Laboratories, Ltd., another DFB affiliate, is a contract pharmaceutical research, development, and manufacturing services company with facilities in San Antonio, Texas, and Lakewood, New Jersey. DPTÂ’s headquarters are in San Antonio.
Schmidt Scientific Taiwan Ltd. (SST) is a value-added distribution company that markets high quality and technology-based products in the medical and electronics fields. SST has operations in Taiwan and China.
###
